The purpose of the study was to assess the toxicity and efficacy of an oral, combination antiemetic regimen including granisetron (Kytril; SmithKline Beecham High-dose chemotherapy (HDC) with peripheral blood Pharmaceuticals, Philadelphia, PA, USA) in the setting stem cell transplantation (PBSCT) is a potentially valuable of highly emetogenic conditioning chemotherapy for therapy for a variety of neoplastic diseases. The chemotherstem cell transplantation. Antiemetic prophylaxis conapeutic agents used in this setting, particularly alkylators sisted of oral granisetron 2 mg once daily, oral prochlorand carboplatin, induce significant nausea and emesis even perazine 10 mg q 6 h and oral dexamethasone 4 mg q at lower doses. At the doses used in HDC regimens, these 6 h, beginning 1 h prior to chemotherapy on each of the drugs are highly emetogenic and can result in significant 4 days of chemotherapy and continuing until 24 h after morbidity for patients. 1,2 Control of these side-effects can the completion of high-dose chemotherapy (HDC).
,
antiemetics, often with disagreeably sedating properties. VP-16 1800 mg/m 2 and carboplatin 1200 mg/m 2 ) or CTP The most potent antiemetic agents available, the 5-hyd-(thiotepa 500 mg/m 2 in place of VP-16) in four daily roxytryptamine-3 receptor (5-HT 3 ) or serotonin antagonists, doses given over 4 h from days −4 to −1. Previously have shown superior antiemetic efficacy and low side-effect mobilized and cryopreserved peripheral blood stem profiles when given intravenously to patients receiving cells (PBSC) were reinfused on day +1. Evaluation of high-dose cisplatin (80-100 mg/m 2 ), usually as a single nausea, emetic episodes (EE), adverse events, and rescue dose to chemotherapy-naive patients. 3, 4 By contrast, HDC medications were recorded on a daily patient diary.
is typically administered in a multiple daily dose schedule, Thirty-six patients were entered. Fifty-three percent to patients who have often been heavily pre-treated with (95% CI = 37-75%) of patients achieved complete chemotherapy. Although the published experience of seroresponse for emesis (CR = 0 EE/24 h) and 75% (95% tonin antagonists in the setting of HDC for transplantation CI = 58-90%) had combined complete and major is limited, several small pilot studies have shown encourresponse (CR + MR = 0-3 EE/24 h) during all 5 of the aging results. 5-10 All of these trials utilized intravenous treatment days. During the 5 study days, the average preparations of either ondansetron, granisetron or tropisenumber of patient-days with no emesis was 3.7 (74%) tron, with or without dexamethasone. The rate of 'major and with 1-3 EE was 4.3 (86%). On days −4, −3, −2, −1 control' of emesis (generally defined as Ͼ3 emetic episodes and 0, the combined CR + MR rate for emesis was 97, per 24 h) for these studies ranges from 34 to 91%. 92, 86, 78 and 75%, respectively. Nausea was absent or
Compared to traditional antiemetics administered intramild on all 5 study days in 57% (95% CI = 37-75%).
venously, oral regimens are more convenient for prophyEight patients had severe late-onset emesis occurring on laxis in the outpatient setting, and offer considerable cost days +1 to +3 after reinfusion of stem cells. No clinically savings. Granisetron has recently become available in a significant toxicities attributable to the antiemetic regionce daily oral formulation which appears to have antiemmen were observed. An all oral antiemetic regimen of etic efficacy equal to the intravenous preparation, due to granisetron, prochlorperazine and dexamethasone its excellent absorption across the duodenal mucosa. 11 The appears to be safe and highly effective in patients receivaddition of glucocorticoids enhances the effect of oral graning multiple, daily, high-dose chemotherapy regimens.
isetron significantly. 12-14 Furthermore, combining a dopamThis regimen offers the advantage of cost-savings, a low ine antagonist (eg prochlorperazine) with a serotonin side-effect profile and ease of administration in the preblocker and glucocorticoid appears to maximize control of dominately outpatient setting of HDC with peripheral both acute and delayed emesis. etic regimen combining granisetron, dexamethasone and prochlorperazine, as prophylaxis for acute and delayed nausea and emesis in patients undergoing high-dose chemotherapy with autologous stem cell rescue.
Patients and methods

Patient selection
From November 1995 to October 1996, patients with highrisk or advanced cancer, who were scheduled to undergo first-time HDC, were evaluated. Standard eligibility criteria for HDC were used and included age Ͼ18 or Ͼ60, non-Thiotepa 500 mg/m2/day or VP-16 450 mg/m2/day Carboplatin 300 mg/m2/day Study day
Ciprofloxacin pregnant state, Karnofsky performance status (KPS) Ͼ60%, ineligible for this study if: they had nausea, vomiting or antiemetic use in the 24 h prior to enrollment; previous reaction to any of the antiemetic study drugs or another underlying cause of emesis such as gastric outlet obstrucAssessment of antiemetic efficacy and safety tion or CNS metastases. Patients could not receive concurrent radiotherapy, corticosteroids, benzodiazepines or have Daily assessment of nausea and vomiting was made using a contraindication to glucocorticoid use. Patients may have a patient diary from day −4 to day +1 (acute effect) and had any number of chemotherapy regimens prior to from day +1 to day +8 (late onset effect). Nausea was enrollment and no patient was excluded because of a prior recorded on a 0-10 cm visual analog scale and was graded history of nausea or vomiting with chemotherapy. Patients as absent (0), mild (1-4), or severe (5-10) for each 24 h were questioned regarding their history of nausea or emesis period. 17 An emetic episode (EE) was defined as a single during prior chemotherapy. Patients gave written informed episode of vomiting, a dry retch or continuous emesis with consent approved by the Institutional Human Subjects less than 1 min between separate episodes. Table 1 outlines  Committee. the response criteria. If patients were unable to tolerate a scheduled dose of study medications, they were allowed to receive one dose of sub-lingual lorazepam (1 mg) or oral Chemotherapy and peripheral blood stem cell diphenhydramine (25 mg), followed by attempted repeat transplantation ingestion. If the patient was still unable to take the study All patients received HDC consisting of CVP medication, a secondary rescue regimen of intravenous lor-(cyclophosphamide 6 g/m 2 , VP-16 1800 mg/m 2 , and carazepam or diphenhydramine was available and the oral boplatin 1200 mg/m 2 ) or CTP (thiotepa 500 mg/m 2 instead treatment termed 'failure'. Any patient with Ͼ3 EE in of VP-16) given in divided doses over 4 h from days −4 24 h was considered a study failure and treated at the to −1. One patient received mitoxantrone (60 mg/m 2 ) in discretion of the attending physician. The use of rescue place of cyclophosphamide. Peripheral blood stem cells medications was recorded for each patient. which had been previously mobilized and cryopreserved in Adverse events other than nausea or vomiting were 10% dimethyl sulfoxide (DMSO) were reinfused 48 h after recorded daily in diaries where patients answered specific the last day of chemotherapy. Prophylactic antibiotics conquestions regarding common symptoms known to be sisting of ciprofloxacin 750 mg twice a day and rifampin associated with antiemetic therapy. 300 mg twice a day, and granulocyte colony-stimulating factor, 5 g/kg subcutaneously, were commenced at that Statistics time.
Exact binomial 95% confidence intervals (CI) were determined using Epi-INFO software (CDC, Atlanta, GA, USA).
Antiemetic regimen
Patients received an all oral regimen of granisetron (Kutril; Smithkline Beecham, Philadelphia, PA, USA) 2 mg once Table 1 Response criteria daily, dexamethasone (Decadron; Merck, Sharp and Dohme, West Point, PA, USA) 4 mg q 6 h and prochlorper- treatment days). In total, 53% (95% CI = 37-75%) achieved Results a complete response and 75% (95% CI = 58-90%) had either a complete or major response during the treatment Patient characteristics period. During the 5 days of the study, the average number A total of 52 patients were assessed for the study. Sixteen of patient-days with no emesis was 3.7 (74%) and with 1-patients were excluded prior to enrollment: four patients 3 EE was 4.3 (86%). On days −4, −3, −2, −1 and 0, the with a prior toxic reaction to prochlorperazine, four patients combined complete and major response rate for emesis was with nausea or vomiting 24 h before starting chemotherapy, 97% (35/36), 92% (33/36), 86% (31/36), 78% (28/36) and and eight patients who refused the study because of a pref-75% (27/36), respectively. Of note, 100% of males (8/8) erence for specific antiemetics other than those of the study.
achieved CR during all 5 treatment days compared to 41% These 16 patients were treated with antiemetic regimens at (9/27) of females. Figure 3 illustrates the degree of nausea the discretion of their attending physician. The charactercontrol for all patients during the 5 day study period. Nauistics of the 36 patients enrolled and treated are shown in sea was absent or minor throughout the treatment period in Table 2. 58% (95% CI = 37-75%). Table 3 summarizes the results All 36 patients had prior chemotherapy with less than for acute emesis and nausea for the entire group of patients. 10% describing 'severe' chemotherapy-induced nausea or Severe late-onset emesis, defined as Ͼ3 EE in at least vomiting. Most patients had received either oral or intraone 24 h period after day +1 (following completion of the venous 5HT-3 antagonists as prophylaxis.
4 days of HDC and 1 rest day), occurred in eight of the 27 patients who had not failed during the study period. Of these eight patients, one failed on day +1, three on day +2, Antiemetic efficacy three on day +3, and one on day +4. These data are rep- Figure 2 shows the results for acute emetic control of all resented in Figure 4 . patients during the 5 study days (no EE on any of the study In total, 13 of 36 (36%) patients received doses of lorazepam or diphenhydramine during the 5 study days; seven of these were patients who subsequently failed the regimen. In the other six patients, doses were given primarily at the patients' request for agitation or sleep. patients experienced at least mild nausea although nine patients (25%) reported no nausea at all during the 5 days of study.
Several recent reviews have highlighted the importance of clinical variables related to the patient population in antiemetic trials, including age, gender and prior chemotherapy. 18, 19 With regard to gender, we noted that 100% (8/8) of males had a CR during all 5 treatment days compared to 41% (9 /22) of females. A higher incidence of nausea and vomiting in the sub-group of young women has been previously observed. 20 Conclusions regarding the gender variability of emetogenic response in this study is limited by the small number of patients and the different chemotherapy regimens given to men and women that were disease specific (8/8 males received HDC with CVP; 2/28 experience may help to clarify this issue. Nevertheless, these preliminary results are particularly impressive given the fact that the patients were extensively pre-treated with Safety and adverse events multiple chemotherapy agents, were young (median age 47) The most commonly experienced adverse events are listed and predominately female and the regimen is multiple day. in Table 4 . Restlessness or sedation were the most freThis is in contrast to many antiemetic trials where only quently reported symptoms occurring at some time during chemotherapy-naïve patients, receiving chemotherapy on a the 5 study days. In general, these symptoms were mild single day are included. and did not require alterations in the protocol. Headache
Our results compare favorably with those of intravenous was seen in one third of patients, and was described as serotonin receptor antagonist-based regimens in patients mild in most cases. One patient experienced episodes of undergoing multi-day HDC. In a study by Barbounis and bradycardia during emesis, which required telemetric monicoworkers, 7 intravenous ondansetron alone was administoring, and was thought to be associated with a vasovagal tered q 8 h during the 3 days of high-dose chemotherapy response to retching. and for 5 days following. In 29 patients, the major control rate (Ͻ3 EE in 24 h) for emesis ranged from 76% on day 1 to 52% on day 3 of chemotherapy. Delayed emesis was Dicussion controlled in 67% of patients. A recent study randomized 58 patients, receiving various HDC regimens with or withWe have investigated the efficacy and tolerability of a out total body irradiation, to intravenous granisetron vs novel, all oral antiemetic regimen for use in patients 'standard' metoclopramide-based antiemetic regimens. 9 A exposed to a highly emetogenic, multi-agent, multiple-day significantly higher emetic control rate was observed during high-dose chemotherapy (HDC) regimen. In this study, we the first 24 h of chemotherapy in the granisetron group have shown the combination of granisetron, dexamethasone compared to metoclopramide regimens (87 vs 37%, P Ͻ and prochlorperazine to be highly effective in controlling 0.001) and during the entire period of conditioning (51 vs both acute and late-onset emesis in this setting. 0%, P Ͻ 0.001). We observed an overall complete response rate (no With the pilot oral regimen, approximately half of the emesis) in 53% of patients during all 5 days of antiemetic patients experienced agitation or sedation on at least one prophylaxis with a combined complete and major response of the treatment days (see Table 4 ) but these side-effects rate (0-3 episodes in 24 h) of 75% for each and every day were mild and did not interfere with outpatient treatment of the 5 day study period. As might be expected on the for any patient. Both of these are potential side-effects of basis of cumulative chemotherapy toxicity, emetic control either dexamethasone or prochlorperazine. Headache was declined throughout days of high-dose induction ranging also frequently reported and again was mild in most cases; from 97% on day −4 to 75% on day 0. The majority of this is an expected side-effect of 5-HT 3 blockers. No serious adverse toxicities felt to be directly related to the antiemetics were observed. of the patients, who had not failed during the first 5 day prevention of delayed emesis. 28 Maximal control of late-
